Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis.
In conclusion, edoxaban is likely to provide even better protection from stroke and ICH than placebo, aspirin alone, or aspirin plus clopidogrel in both clinical trial populations and unselected community populations. Both edoxaban doses would also bring a positive NCB compared to anti-platelet drugs or placebo/non-treatment based on 'real world' data.
PMID: 26062437 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Blann AD, Skjøth F, Rasmussen LH, Larsen TB, Lip GY Tags: Thromb Haemost Source Type: research
More News: Aspirin | Atrial Fibrillation | Clinical Trials | Clopidogrel | Hematology | Hemorrhagic Stroke | Ischemic Stroke | Plavix | Stroke | Study | Thrombosis